IGF-1 LR3
Monograph · DLong-arginine-3 IGF-1 analog. Reduced binding to IGFBPs prolongs free IGF-1 activity ~3× standard IGF-1.
How it clearsHalf cleared in ~1d. Most (~96%) gone by ~5d.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Originally developed as a research tool. Bypasses normal IGFBP buffering, leading to higher free-IGF-1 exposure. Physique-community use is widespread; clinical use is essentially nonexistent. Hypoglycemia and tissue-overgrowth concerns are real.
Limited human data. The mechanism touches a sensitive regulatory axis, which means effects — when they appear — tend to be more pronounced than in other categories. Both undershoot and overshoot are real outcomes here. This is the tier where tracking matters most and flying blind costs most.
No human clinical use. Hypoglycemia risk is real. Long-term tissue-overgrowth and cancer-promotion concerns. Identity verification of grey-market product is poor.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyStack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Mecasermin (recombinant IGF-1) is FDA-approved as Increlex for severe primary IGF-1 deficiency in pediatric growth disorders. IGF-1 LR3 is a long-acting analog used in research and bodybuilding contexts; not separately FDA-approved. Clinical IGF-1 replacement data is solid for the narrow approved indication.
A-tier — "more substantial research around it. It is an actual proven downstream of growth hormone being higher, which we obviously know is very anabolic." Uses 40 mcg pre-workout. Argues IGF-1 LR3 should NOT be paired with GH — they target the same pathway.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 20-50 µg · daily, subcutaneous
Draw volume is below 5 units — hard to measure accurately on most syringes. Consider adding more BAC water to dilute, or moving to a smaller syringe.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.